ACM
OCUL icon

AlphaCrest Capital Management’s Ocular Therapeutix OCUL Stock Holding History

AlphaCrest Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-53,700
Closed -$761K – 1345
2021
Q2 		$761K Buy
+53,700
New +$816K 0.03% 784

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AlphaCrest Capital Management's OCUL Position: Q3 2021 in Review

AlphaCrest Capital Management sold out of Ocular Therapeutix (OCUL) in Q3 2021, closing a stake of 53,700 shares — an estimated $761K sold.

AlphaCrest Capital Management first reported a position in OCUL in Q2 2021 and held it in 1 quarter. The position peaked at $761K in Q2 2021. 141 funds tracked by Wall St. Rank hold OCUL as of Q3 2021.

  • AlphaCrest Capital Management reported no remaining Ocular Therapeutix position as of Q3 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 53,700 Ocular Therapeutix shares in Q3 2021, an estimated $761K.
  • AlphaCrest Capital Management first reported a position in Ocular Therapeutix in Q2 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's Ocular Therapeutix position peaked at $761K in Q2 2021.
  • 141 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2021.

Based on AlphaCrest Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.